Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid ...

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

Viking Therapeutics inks broad manufacturing pact with CordenPharma to support commercialization of VK2735: San Diego Wednesday, March 12, 2025, 17:00 Hrs [IST] Viking Therapeutic ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

CEO Brian Lian highlighted 2024 as an exceptionally ... as higher doses are explored in oral VK2735 trials. Viking Therapeutics showcased significant clinical progress across its pipeline in ...

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...

Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ensure supply.

The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA. Read More on VKTX: Viking Therapeutics NewsMORE Related Stocks Indices ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

"We are excited to enter into this agreement with one of the world's leading CDMOs in the peptide space," said Brian Lian, Ph.D., chief executive officer of Viking Therapeutics. "We have a long ...